{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:17:46Z","timestamp":1767388666815,"version":"3.48.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104945","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:28:53Z","timestamp":1758133733000},"page":"104945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival outcomes with enfortumab vedotin\u2013containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"given":"Muhammad","family":"Ansab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazal","family":"Ishaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiman","family":"Araib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umama","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104945_bib1","unstructured":"A Revised Introduction to the R-Index | Replicability-Index.n.d."},{"key":"10.1016\/j.critrevonc.2025.104945_bib2","unstructured":"Automeris.Io: Computer Vision Assisted Data Extraction from Charts Using WebPlotDigitizer Available online: https:\/\/automeris.io\/ (accessed on 27 April 2025)."},{"key":"10.1016\/j.critrevonc.2025.104945_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up\u2606","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib6","doi-asserted-by":"crossref","first-page":"A419","DOI":"10.1016\/j.jval.2017.08.127","article-title":"Epidemiology of locally advanced or metastatic urothelial cancer in the US, Europe and Japan","volume":"20","author":"Bharmal","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2025.104945_bib7","unstructured":"Bladder Cancer Statistics | World Cancer Research Fund.n.d."},{"key":"10.1016\/j.critrevonc.2025.104945_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib9","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2025.03.010","article-title":"Cost-Effectiveness of enfortumab vedotin and pembrolizumab for First-Line metastatic urothelial cancer in the United States","author":"Chiddarwar","year":"2025","journal-title":"Value Health"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104945_bib11","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in nectin4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104945_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24559","article-title":"Potential role of immunotherapy and targeted therapy in the treatment of cancer: a contemporary nursing practice","volume":"10","author":"Dailah","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104945_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/curroncol31020056","article-title":"Real-world insights into efficacy and safety of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma: findings, considerations, and future directions","volume":"31","author":"Endo","year":"2024","journal-title":"Curr. Oncol."},{"journal-title":"LiverTox Clin. Res. Inf. Drug-Induc. Liver Inj.","year":"2023","author":"Enfortumab Vedotin","key":"10.1016\/j.critrevonc.2025.104945_bib14"},{"key":"10.1016\/j.critrevonc.2025.104945_bib15","doi-asserted-by":"crossref","unstructured":"\u897f\u539f\u8056\u9855; \u9ed2\u702c\u6d69\u6587; \u4f0a\u6771\u76f4\u57ce; \u5927\u897f\u8061; \u5e73\u91ce\u6cf0\u55e3; \u672b\u91d1\u5b8f\u57fa; \u6e21\u8fba\u6643\u592a; \u7bc9\u4e95\u514b\u8061; \u690d\u7530\u6d69\u4ecb; \u4e0a\u6751\u6176\u4e00\u90ce; et al. \u5f53\u9662\u306b\u304a\u3051\u308b\u8ee2\u79fb\u30fb\u9032\u884c\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u5bfe\u3059\u308bEnfortumab Vedotin\u306e\u521d\u671f\u4f7f\u7528\u7d4c\u9a13. \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u96d1\u8a8c 2024, 115, 21\u201327, doi:10.5980\/jpnjurol.115.21.","DOI":"10.5980\/jpnjurol.115.21"},{"key":"10.1016\/j.critrevonc.2025.104945_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.15368","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","volume":"31","author":"Fukuokaya","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00401706.1988.10488400","article-title":"Graphical display of estimates having differing standard errors","volume":"30","author":"Galbraith","year":"1988","journal-title":"Technometrics"},{"key":"10.1016\/j.critrevonc.2025.104945_bib18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1740774507079441","article-title":"An exploratory test for an excess of significant findings","volume":"4","author":"Ioannidis","year":"2007","journal-title":"Clin. Trials"},{"key":"10.1016\/j.critrevonc.2025.104945_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with Muscle-Invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib23","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.clgc.2023.05.007","article-title":"Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors or enfortumab vedotin","volume":"21","author":"Jindal","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib24","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.3390\/cancers15174227","article-title":"Administration of enfortumab vedotin after immune-checkpoint inhibitor and the prognosis in Japanese metastatic urothelial carcinoma: a large database study on enfortumab vedotin in metastatic urothelial carcinoma","volume":"15","author":"Kawahara","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104945_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2020.07.003","article-title":"Association between the occurrence and spectrum of Immune-Related adverse events and efficacy of pembrolizumab in asian patients with advanced urothelial cancer: multicenter retrospective analyses and systematic literature review","volume":"19","author":"Kijima","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib26","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102216","article-title":"Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: a multicenter retrospective study in Japan","volume":"16","author":"Kobari","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70368","article-title":"Phase 2 trial of enfortumab vedotin in patients with previously treated locally advanced or metastatic urothelial carcinoma in China","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2025.104945_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib31","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.21873\/anticanres.17162","article-title":"Clinical outcomes of enfortumab vedotin in advanced urothelial carcinoma with prior avelumab versus pembrolizumab therapy","volume":"44","author":"Minato","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2025.104945_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102148","article-title":"Organ-Specific tumor response to enfortumab vedotin for metastatic urothelial carcinoma: a multicenter retrospective study","volume":"22","author":"Minato","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib33","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2025.104945_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following Platinum-Based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre Real-World Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib35","doi-asserted-by":"crossref","DOI":"10.5001\/omj.2022.96","article-title":"Programmed death-ligand 1 (PD-L1) expression in bladder cancer and its correlation with tumor grade, stage, and outcome","volume":"37","author":"Nabhani","year":"2022","journal-title":"Oman Med. J."},{"key":"10.1016\/j.critrevonc.2025.104945_bib36","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jjco\/hyae101","article-title":"Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma","volume":"54","author":"Nakagawa","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10147-024-02678-x","article-title":"Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma","volume":"30","author":"Nakagawa","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab vedotin for metastatic urothelial carcinoma: comprehensive treatment outcomes and prognostic insights from a multicenter Real-World study (YUSHIMA Study)","volume":"23","author":"Nakamura","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib39","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers16152648","volume":"16","author":"Nakane","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104945_bib40","article-title":"Real-World evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study","volume":"23","author":"Niedersuess-Beke","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib41","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in Cisplatin-Ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib42","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"journal-title":"Shubhrampandey\/metaSurvival","year":"2024","author":"Pandey","key":"10.1016\/j.critrevonc.2025.104945_bib43"},{"key":"10.1016\/j.critrevonc.2025.104945_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib47","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: exploratory analysis of Nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (La\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.664","article-title":"EV-302: updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (La\/mUC)","volume":"43","author":"Powles","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102574","article-title":"Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer","volume":"90","author":"Reike","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non\u2013muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Rhijn","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70479","article-title":"Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience","volume":"14","author":"Rizzo","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104945_bib52","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib53","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 Long-Term outcomes: 24-Month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma \u2606","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib54","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4\u2013Positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.412","article-title":"Trends over time in survival in patients with urothelial carcinoma in the Real-World: a multicenter analysis","volume":"39","author":"Samnani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib56","article-title":"Real-world effectiveness of single-agent enfortumab vedotin in patients with advanced urothelial carcinoma","volume":"23","author":"Sayegh","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104945_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102183","article-title":"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"16","author":"Shindo","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib58","first-page":"224","article-title":"First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure","volume":"27","author":"Sikora-Kupis","year":"2024","journal-title":"Contemp. Oncol. Onkol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.critrevonc.2025.104945_bib60","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104945_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4581","article-title":"Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)","volume":"42","author":"Sternschuss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib62","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in Post-Platinum, Post-Pembrolizumab advanced urothelial carcinoma: a multicenter propensity Score-Matched study","volume":"30","author":"Taguchi","year":"2023","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib63","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104945_bib64","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3390\/cancers16173071","article-title":"Mechanistic insights into the successful development of combination therapy of enfortumab vedotin and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer","volume":"16","author":"Taylor","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104945_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.684","article-title":"Primary tumor response to enfortumab vedotin with\/without pembrolizumab in patients with upper tract urothelial cancer","volume":"43","author":"Vlachou","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib66","doi-asserted-by":"crossref","first-page":"1377842","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin\u2013related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/CAD.0000000000001449","article-title":"Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Anticancer. Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104945_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104945_bib69","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104945_bib70","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in Cisplatin-Ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, Single-Arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104945_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a european multicenter Real-World patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur. Urol. Open Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:16:28Z","timestamp":1767388588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":71,"alternative-id":["S1040842825003336"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104945","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes with enfortumab vedotin\u2013containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104945"}}